Chinese biotechs test the waters of novel technology platforms
Few platform companies are attracting top funding in China — at least not yet
Few platform companies are attracting top funding in China, but as the Chinese biotech sector evolves, it’s sampling new technologies through product licensing deals.
The Chinese biotechs attracting the most funding are accessing a growing number of innovative products through licensing deals, but so far, few have taken on the risk of developing technology platforms in-house. That picture could soon change.
BioCentury’s analysis of the 97 Chinese biotechs that have raised over $100 million in venture funding